Suppr超能文献

原发性膜性肾病蛋白尿缓解的预后因素

Prognostic Factors of Proteinuria Remission in Primary Membranous Nephropathy.

作者信息

Krakowska-Jura Kornelia, Kler Anna Natalia, Wajerowska Weronika, Konieczny Andrzej, Banasik Mirosław

机构信息

Clinical Department of Nephrology, Transplantation Medicine and Internal Diseases, Institute of Internal Diseases, Wroclaw Medical University, 50-565 Wroclaw, Poland.

Faculty of Medicine, Wroclaw Medical University, 50-565 Wroclaw, Poland.

出版信息

J Clin Med. 2025 Apr 22;14(9):2880. doi: 10.3390/jcm14092880.

Abstract

Primary membranous nephropathy is a leading cause of nephrotic syndrome in adults, characterized by immune complex deposition in the glomerular basement membrane. Predicting proteinuria remission is essential for guiding treatment decisions, optimizing immunosuppressive therapy, and improving renal outcomes. Traditional prognostic markers, such as anti-PLA2R antibody status and baseline proteinuria levels, offer valuable insights into disease progression. However, recent research has identified additional biomarkers that may enhance risk stratification and refine individualized treatment strategies. Serum-based markers, such as uric acid and inflammatory indices, may indicate systemic changes that impact disease progression. Urinary biomarkers, including microhematuria, α1-microglobulin, and CXCL13, have been proposed as potential predictors of disease activity and remission likelihood. Furthermore, histopathological features, such as glomerular basement membrane thickness, tubulointerstitial injury, and acute kidney injury, provide structural correlates that may inform prognosis. This review explores both established and emerging prognostic indicators across various biological domains. Understanding these predictors can aid in developing personalized therapeutic strategies, optimizing disease management, and improving patient outcomes in primary membranous nephropathy.

摘要

原发性膜性肾病是成人肾病综合征的主要病因,其特征是免疫复合物沉积于肾小球基底膜。预测蛋白尿缓解对于指导治疗决策、优化免疫抑制治疗以及改善肾脏预后至关重要。传统的预后标志物,如抗磷脂酶A2受体(anti-PLA2R)抗体状态和基线蛋白尿水平,为疾病进展提供了有价值的见解。然而,最近的研究发现了其他生物标志物,可能会加强风险分层并完善个体化治疗策略。基于血清的标志物,如尿酸和炎症指标,可能表明影响疾病进展的全身变化。尿生物标志物,包括微量血尿、α1-微球蛋白和CXCL13,已被提议作为疾病活动和缓解可能性的潜在预测指标。此外,组织病理学特征,如肾小球基底膜厚度、肾小管间质损伤和急性肾损伤,提供了可能有助于判断预后的结构相关性。本综述探讨了各个生物学领域中已确立和新出现的预后指标。了解这些预测指标有助于制定个性化治疗策略、优化疾病管理并改善原发性膜性肾病患者的预后。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a12c/12072736/60585ab10598/jcm-14-02880-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验